Carboxypeptidase B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJingxuan Liu, James D. McIninch, Patrick Haslett
Life of this patent
Estimating the term…
Abstract
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the CPB2 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CPB2 gene and to methods of preventing and treating a CPB2-associated disorder, e.g., a disorder associated with thrombosis.
Claims30
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of carboxypeptidase B2 (CPB2) in a cell, wherein the dsRNA agent comprises a sense strand and an antisense strand, wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2.
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of carboxypeptidase B2 (CPB2), wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region, wherein the sense strand comprises at least 19 contiguous nucleotides from any one of the nucleotide sequence of nucleotides 92-114, 189-211, 322-344, 421-443, 662-684, 700-722, 753-755,876-898, 965-987, 1080-1102, 1139-1161, or 1411-1433 of SEQ ID NO:1, and the antisense strand comprises at least 19 contiguous nucleotides from the corresponding nucleotide sequence of SEQ ID NO:2.
-6. (canceled)
(canceled)
(canceled)
-20. (canceled)
(canceled)
(canceled)
-44. (canceled)
-54. (canceled)
-62. (canceled)
(canceled)
Dependencies are inferred from the claim text.